Our second major publication this year is out — in Science Translational Medicine!
We’re proud to share the results of an international, multi-institute, and multi-company collaboration aiming to bring our macrophage-based therapy MDC-735 closer to patients.
The research article, “Adoptive cell therapy with macrophage-drug conjugates facilitates cytotoxic drug transfer and immune activation in glioblastoma models,” highlights how engineered macrophages can simultaneously deliver cytotoxic drugs and stimulate the immune system — a promising strategy for hard-to-treat tumors.
This work was supported by the European Research Council (ERC) (AGAINST 101113272), ProMedica Foundation, NCBR Fast Track grant POIR.01.01.01-00-0362/20, Swiss Cancer League (KFS-5763-02-2023), Baasch-Medicus Foundation, Helmut Horten Foundation, and Sophien Foundation — thank you for making this possible.
Congratulations and deep thanks to all co-authors: Miaomiao Sun, Maciej Białasek, Maud Mayoux, Meng-Syuan Lin, Ph.D., Alicia Buck, Ilona Marszałek, Bartłomiej Taciak, Marcel Bühler, Małgorzata Górczak, Paulina Kucharzewska, Daria Kurpiel, Małgorzata Siemińska, Julia Nowakowska, Jan Brancewicz, Konrad Gabrusiewicz, Waldemar Lipiński, Sibylle Pfammatter, Steve Pascolo, Gregor Hutter, Lubomir Bodnar, Berend Snijder, Luca Regli, Michael Weller, Martin Baumgartner, Sonia Tugues, Tomasz Rygiel, Magdalena Król, and Tobias Weiss.
We encourage everyone working in immunotherapy and cell-based oncology to take a look:
https://www.science.org/doi/10.1126/scitranslmed.adr4058
